Akebia Therapeutics(AKBA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted ...